Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Albertella, M. et al. (2008) Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study. Clinical Cancer Research, 14(4), pp. 1096-1104.

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Rampling, Professor Roy
Authors: Albertella, M., Loadman, P., Jones, P., Phillips, R., Rampling, R., Burnet, N., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C., Harris, P., Wong, A., Lalani, A., and Twelves, C.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Clinical Cancer Research

University Staff: Request a correction | Enlighten Editors: Update this record